Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous cluster immunotherapy for grass pollen allergy
2024-517521-25-00Phase 3Authorised
- Sponsor
- ROXALL Medizin GmbH
- Start
- Aug 2025
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 4
01
Overview
Phase 3, randomised, double-blind trial of allergen extract from phleum pratense pollen, glutaraldehyde-modified in allergic rhinitis (AR), allergic rhinoconjunctivitis (ARC) and grass pollen allergy (4 arms), sponsored by ROXALL Medizin GmbH. Primary endpoint: Absolute difference in mean Combined Symptom and Medication Score (CSMS) during Peak Grass Pollen Period (PGPP). Planned start Aug 2025; status: authorised.
02
Drugs
allergen extract from phleum pratense pollen, glutaraldehyde-modified
03
Conditions
allergic rhinitis (AR)allergic rhinoconjunctivitis (ARC)grass pollen allergy
Beyond the preview
Go deeper on 2024-517521-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517521-25-00.